

# Diabetic Retinopathy Market - 2023-2031

<https://marketpublishers.com/r/D8A219F95441EN.html>

Date: May 2025

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: D8A219F95441EN

## Abstracts

The Diabetic Retinopathy Market was valued at US\$ 7,167.00 million in 2023 and is anticipated to reach US\$ 11,702.89 million by 2031, at a CAGR of 0.064 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Diabetic Retinopathy Market.

This report delivers a comprehensive overview of the Diabetic Retinopathy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Diabetic Retinopathy Market. The Diabetic Retinopathy Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

Diabetic Retinopathy Market Scope:

By Indication Type

Non-Proliferative Diabetic Retinopathy

Proliferative Diabetic Retinopathy

### By Treatment Type

Anti-Vascular Endothelial Growth Factor (VEGF)

Intraocular Steroid Injection

Laser Surgery

Vitreectomy

Others

### By End User

Hospitals

Ophthalmic Clinics

Ambulatory Surgical Center

Others

### Key Players

Abbott Laboratories

Alimera Science

Allergan plc

Ampio Pharmaceuticals.

Bayer AG

Hoffmann-La Roche

Novartis International AG

Glycadia Pharmaceuticals

Regeneron Pharmaceuticals Inc.

Valeant Pharmaceutical

## Major Highlights

This report delivers a comprehensive overview of the Diabetic Retinopathy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Diabetic Retinopathy Market. The Diabetic Retinopathy Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the

latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### **1. METHODOLOGY AND SCOPE**

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### **2. MARKET DEFINITION AND OVERVIEW**

### **3. EXECUTIVE SUMMARY**

### **4. MARKET DYNAMICS**

#### 4.1. Market Impacting Factors

##### 4.1.1. Drivers

4.1.1.1. Technological advancement in diagnosing diabetic retinopathy is expected to drive market growth.

##### 4.1.2. Restraints:

4.1.2.1. Side effects associated with the drugs treating diabetic retinopathy are expected to hamper the market growth.

##### 4.1.3. Opportunity

##### 4.1.4. Impact Analysis

### **5. INDUSTRY ANALYSIS**

#### 5.1. Porter's Five Forces

#### 5.2. Supply Chain

#### 5.3. Pricing Analysis

### **6. COVID-19 ANALYSIS**

#### 6.1. Analysis of Covid-19 on the Market

##### 6.1.1. Before COVID-19 Market Scenario

##### 6.1.2. Present COVID-19 Market Scenario

##### 6.1.3. After COVID-19 or Future Scenario

#### 6.2. Pricing Dynamics Amid Covid-19

#### 6.3. Demand-Supply Spectrum

#### 6.4. Government Initiatives Related to the Market During Pandemic

#### 6.5. Manufacturers Strategic Initiatives

## 6.6. Conclusion

## 7. BY INDICATION TYPE

### 7.1. Introduction

7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type

7.1.2. Market Attractiveness Index, By Indication Type

### 7.2. Non-Proliferative Diabetic Retinopathy\*

7.2.1. Introduction

7.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029

### 7.3. Proliferative Diabetic Retinopathy

## 8. BY TREATMENT TYPE

### 8.1. Introduction

8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

8.1.2. Market Attractiveness Index, By Treatment Type

### 8.2. Anti-Vascular Endothelial Growth Factor (VEGF)\*

8.2.1. Ranibizumab (Lucentis)\*

8.2.1.1. Introduction

8.2.1.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029

8.2.2. Aflibercept intravitreal (Eylea)

8.2.3. Others

### 8.3. Intraocular Steroid Injection

### 8.4. Laser Surgery

### 8.5. Vitrectomy

### 8.6. Others

## 9. BY END USER

### 9.1. Introduction

9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

9.1.2. Market Attractiveness Index, By End User

### 9.2. Hospitals

9.2.1. Introduction

9.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029

- 9.3. Ophthalmic Clinics
- 9.4. Ambulatory Surgical Center
- 9.5. Others

## **10. BY REGION**

### 10.1. Introduction

10.1.1. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region

10.1.2. Market Attractiveness Index, By Region

### 10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type

10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.2.6.1. U.S.

10.2.6.2. Canada

10.2.6.3. Mexico

### 10.3. Europe

10.3.1. Introduction

10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type

10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.3.6.1. Germany

10.3.6.2. U.K.

10.3.6.3. France

10.3.6.4. Italy

10.3.6.5. Spain

10.3.6.6. Rest of Europe

### 10.4. South America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type

10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

- 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
- 10.5. Asia Pacific
  - 10.5.1. Introduction
  - 10.5.2. Key Region-Specific Dynamics
  - 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
  - 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  - 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  - 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    - 10.5.6.1. China
    - 10.5.6.2. India
    - 10.5.6.3. Japan
    - 10.5.6.4. Australia
    - 10.5.6.5. Rest of Asia Pacific
- 10.6. Middle East and Africa
  - 10.6.1. Introduction
  - 10.6.2. Key Region-Specific Dynamics
  - 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
  - 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  - 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

## **11. COMPETITIVE LANDSCAPE**

- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis

## **12. COMPANY PROFILES**

- 12.1. Abbott Laboratories\*
  - 12.1.1. Company Overview
  - 12.1.2. Product Portfolio and Description
  - 12.1.3. Key Highlights
  - 12.1.4. Financial Overview
- 12.2. Alimera Science
- 12.3. Allergan plc
- 12.4. Ampio Pharmaceuticals.

- 12.5. Bayer AG
- 12.6. Hoffmann-La Roche
- 12.7. Novartis International AG
- 12.8. Glycadia Pharmaceuticals
- 12.9. Regeneron Pharmaceuticals Inc.
- 12.10. Valeant Pharmaceutical (\*LIST NOT EXHAUSTIVE)

### **13. DATAM**

- 13.1. Appendix
- 13.2. About Us and Applications
- 13.3. Contact Us

## I would like to order

Product name: Diabetic Retinopathy Market - 2023-2031

Product link: <https://marketpublishers.com/r/D8A219F95441EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D8A219F95441EN.html>